Lilly announces a new cancer deal, paying Ajax up to $2.3B for JAK inhibitor

Eli Lilly keeps putting its GLP-1 windfall to use. On Monday, the anti-obesity drugmaker announced its latest deal to expand its pipeline of future drugs, saying it would spend as much as